Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing?

Did you know that bacteria have antibacterial properties? Its true.

We spoke to Dr Catherine O’neill CEO of Skinbiotix Plc (LON:SBTX) who said, ‘Its worth remembering that penicillin, one of the first antibiotics to be used medically, is derived from a mould. Micro-organisms make antibacterial compounds against each other. Against this background, the hope is that new antibiotics will be discovered in the human microbiome that will help in the fight against antibiotics resistance.’

In a world where antibiotic resistance is becoming a major problem, scientists race in search for alternatives. Could bacteria provide much-needed strategies to prevent life-threatening infections? The following article provides valuable insight into this and more: https://www.medicalnewstoday.com/articles/318765.php

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.”

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based

    SkinBiotherapeutics Plc

    What Is Dyshidrotic Eczema, Exactly?

    If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop up as crazy itchy blisters on

    SkinBiotherapeutics Plc

    Bacteria on your skin could speed healing

    Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known

    SkinBiotherapeutics Plc

    Can you really use probiotics to fight acne?

    If you’ve ever had a breakout, you’ve likely tried to dry those suckers up with bacteria-killing washes and spot treatments. You know, because conventional wisdom (and lots of research) has shown that zits, particularly the big painful

    SkinBiotherapeutics Plc

    SkinBiotherapeutics is harnessing the power of Microbiome

    SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt